,sentence,pubmed_id,content,label,labeler
0,"2 |||  ||| 0.2 ||| A total of 909 patients were randomized to receive placebo or nebivolol 1.25, 2.5, 5, 10, 20, or 40 mg once daily for up to 84 days.",17786067,909 patients,po.Size,HeYingzhi
1,"2 |||  ||| 0.2 ||| A total of 909 patients were randomized to receive placebo or nebivolol 1.25, 2.5, 5, 10, 20, or 40 mg once daily for up to 84 days.",17786067,84 days,i.Procedure,HeYingzhi
2,"28 ||| RESultS ||| 2.3 ||| Of the 166 patients randomized to nebivolol 40 mg, 147 patients (88.6%) had their dosage increased from the initial 30-mg once-daily to a 40-mg once daily dose, and 19 patients remained at a 30-mg dose.",17786067,"randomized to nebivolol 40 mg, 147 patients (88.6%) had their dosage increased from the initial 30-mg once-daily to a 40-mg once daily dose, and 19 patients remained at a 30-mg dose.",i.Procedure,HeYingzhi
3,"2 |||  ||| 0.2 ||| A total of 909 patients were randomized to receive placebo or nebivolol 1.25, 2.5, 5, 10, 20, or 40 mg once daily for up to 84 days.",17786067,"receive placebo or nebivolol 1.25, 2.5, 5, 10, 20, or 40 mg once daily",i.Procedure,HeYingzhi
4,"51 ||| DiSCuSSioN ||| 3.3 ||| Nebivolol treatment also showed safety and tolerability comparable to placebo overall, except at high doses, with incidences of aes and withdrawal rates comparable to those of placebo over the duration of this trial.",17786067,"safety and tolerability comparable to placebo overall, except at high doses, with incidences of aes and withdrawal rates comparable to those of placebo over the duration of this trial",o.Treatment,HeYingzhi
5,49 ||| DiSCuSSioN ||| 3.1 ||| the results of the present dose-ranging study indicate that once-daily nebivolol is an effective antihypertensive agent in patients with mild to moderate hypertension.,17786067,once-daily nebivolol is an effective antihypertensive agent in patients with mild to moderate hypertension,o.Treatment,HeYingzhi
